Rayonier Advanced Materials Inc (RYAM) Fair Value & Analysis
Basic Materials · US · Market cap $553M
Analysis
Rayonier Advanced Materials Inc (RYAM) currently trades at $8.07, while our model-based Fair Value estimate is $14.08 — implying the stock looks roughly 74.5% undervalued today. We read business quality at 94/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Rayonier Advanced Materials Inc. manufactures and sells cellulose specialty products in the United States, China, Europe, Japan, rest of Asia, Canada, Latin America, and internationally. It operates through Cellulose Specialties, Biomaterials, Cellulose Commodities, Paperboard, and High-Yield Pulp. The company's products include cellulose specialties, which are natural polymers that are used as raw materials to manufacture a range of consumer-oriented products, such as liquid crystal displays, impact-resistant plastics, thickeners for food products, pharmaceuticals, cosmetics, cigarette filters, high-tenacity rayon tire cords and industrial hoses, food casings, paints, lacquers, munitions, and explosives; and biomaterials, including biofuels, lignosulfonates, prebiotics, tall oil soap, and HCE and turpentine. It also offers commodity products, such as commodity viscose used in woven applications, including rayon textiles for clothing and other fabrics, as well as in non-woven applic…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.